Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
2011 1
2013 4
2014 2
2015 3
2016 6
2017 5
2018 7
2019 9
2020 10
2021 16
2022 13
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Kaufman HL, Seebach F, Lowy I, Yoo SY, Mathias M, Fenech K, Han H, Fury MG, Rischin D. Gross ND, et al. Among authors: swiecicki pl. N Engl J Med. 2022 Oct 27;387(17):1557-1568. doi: 10.1056/NEJMoa2209813. Epub 2022 Sep 12. N Engl J Med. 2022. PMID: 36094839 Free PMC article. Clinical Trial.
Management of Salivary Gland Malignancy: ASCO Guideline.
Geiger JL, Ismaila N, Beadle B, Caudell JJ, Chau N, Deschler D, Glastonbury C, Kaufman M, Lamarre E, Lau HY, Licitra L, Moore MG, Rodriguez C, Roshal A, Seethala R, Swiecicki P, Ha P. Geiger JL, et al. Among authors: swiecicki p. J Clin Oncol. 2021 Jun 10;39(17):1909-1941. doi: 10.1200/JCO.21.00449. Epub 2021 Apr 26. J Clin Oncol. 2021. PMID: 33900808
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, Chai-Ho W, Oppelt P, Ghosh D, Bykowski J, Molinolo A, Pittman E, Estrada MV, Gold K, Daniels G, Lippman SM, Natsuhara A, Messer K, Cohen EEW. Sacco AG, et al. Among authors: swiecicki p. Lancet Oncol. 2021 Jun;22(6):883-892. doi: 10.1016/S1470-2045(21)00136-4. Epub 2021 May 11. Lancet Oncol. 2021. PMID: 33989559 Clinical Trial.
Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment.
Derry JMJ, Burns C, Frazier JP, Beirne E, Grenley M, DuFort CC, Killingbeck E, Leon M, Williams C, Gregory M, Houlton J, Clayburgh D, Swiecicki P, Huszar D, Berger A, Klinghoffer RA. Derry JMJ, et al. Among authors: swiecicki p. Clin Cancer Res. 2023 Sep 15;29(18):3813-3825. doi: 10.1158/1078-0432.CCR-23-0827. Clin Cancer Res. 2023. PMID: 37389981 Free PMC article. Clinical Trial.
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.
Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Yoo SY, Mathias M, Han H, Seebach F, Lowy I, Fury MG, Rischin D. Gross ND, et al. Among authors: swiecicki pl. Lancet Oncol. 2023 Nov;24(11):1196-1205. doi: 10.1016/S1470-2045(23)00459-X. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875144 Clinical Trial.
Cold agglutinin disease.
Swiecicki PL, Hegerova LT, Gertz MA. Swiecicki PL, et al. Blood. 2013 Aug 15;122(7):1114-21. doi: 10.1182/blood-2013-02-474437. Epub 2013 Jun 11. Blood. 2013. PMID: 23757733 Free article. Review.
Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma.
Bhambhani C, Sandford E, Haring CT, Brummel C, Tuck KL, Olesnavich M, Bhangale AD, Walline HM, Dermody SM, Spector ME, Chinn SB, Casper K, Mierzwa M, Swiecicki PL, Chad Brenner J, Tewari M. Bhambhani C, et al. Among authors: swiecicki pl. Oral Oncol. 2023 Aug;143:106436. doi: 10.1016/j.oraloncology.2023.106436. Epub 2023 Jun 1. Oral Oncol. 2023. PMID: 37269557
Trans-Renal Cell-Free Tumor DNA for Urine-Based Liquid Biopsy of Cancer.
Dermody SM, Bhambhani C, Swiecicki PL, Brenner JC, Tewari M. Dermody SM, et al. Among authors: swiecicki pl. Front Genet. 2022 Apr 27;13:879108. doi: 10.3389/fgene.2022.879108. eCollection 2022. Front Genet. 2022. PMID: 35571046 Free PMC article. Review.
Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer.
Smith JD, Ludwig ML, Bhangale AD, Brummel C, Swiecicki PL, Worden FP, Chinn SB, Stucken CL, Rosko AJ, Prince MEP, Malloy KM, Casper KA, Bradford CR, Chepeha DB, Shah J, Schonewolf CA, McHugh JB, Nyati MK, Eisbruch A, Mierzwa ML, Spector ME, Brenner JC. Smith JD, et al. Among authors: swiecicki pl. Head Neck. 2023 May;45(5):1281-1287. doi: 10.1002/hed.27344. Epub 2023 Mar 18. Head Neck. 2023. PMID: 36932871 Clinical Trial.
75 results